Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences, Inc. (RCUS)
Price$26.15Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.0M | $51.0M | $37.0M | $38.0M | $383.0M | $78.0M | $15.0M | $8.4M | $1.4M | — |
| Research & development | $523.0M | $448.0M | $340.0M | $288.0M | $257.0M | $159.0M | $78.5M | $49.6M | $47.2M | $14.2M |
| Operating expenses | $633.0M | $588.0M | $457.0M | $392.0M | $329.0M | $202.0M | $103.7M | $63.2M | $54.9M | $18.2M |
| Operating income | −$386.0M | −$330.0M | −$340.0M | −$280.0M | $54.0M | −$124.0M | −$88.7M | −$54.9M | −$53.4M | −$18.2M |
| Operating margin | −1,169.70% | −647.06% | −918.92% | −736.84% | 14.10% | −158.97% | −591.39% | −656.76% | −3,782.09% | — |
| EBITDA | −$376.0M | −$320.0M | −$332.0M | −$274.0M | $58.0M | −$121.0M | −$85.1M | −$51.2M | −$50.8M | −$16.9M |
| EBITDA margin | −1,139.39% | −627.45% | −897.30% | −721.05% | 15.14% | −155.13% | −567.54% | −612.89% | −3,597.24% | — |
| Net income | −$353.0M | −$283.0M | −$307.0M | −$267.0M | $53.0M | −$123.0M | −$84.7M | −$49.6M | −$53.1M | −$18.0M |
| Net profit margin | −1,069.70% | −554.90% | −829.73% | −702.63% | 13.84% | −157.69% | −564.73% | −593.73% | −3,756.69% | — |
| Basic EPSper basic share | -$3.29 | -$3.14 | -$4.15 | -$3.71 | $0.76 | -$2.24 | -$1.93 | -$1.43 | -$29.03 | -$20.80 |
| Diluted EPSper diluted share | -$3.29 | -$3.14 | -$4.15 | -$3.71 | $0.71 | -$2.24 | -$1.93 | -$1.43 | -$29.03 | -$20.80 |
Owners
Reported shareholders
24.74%of listed shares
GILEAD SCIENCES, INC.31.42M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
GILEAD SCIENCES, INC. | 24.74%31.42M shares |
BlackRock, Inc. | 12.93%16.42M shares |
STATE STREET CORP | 4.75%6.03M shares |
WELLINGTON MANAGEMENT GROUP LLP | 4.64%5.9M shares |
MONTANOVA CAPITAL, LLC | 3.76%4.78M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.52%4.48M shares |
FMR LLC | 3.19%4.05M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.06%3.89M shares |
CITADEL ADVISORS LLC | 2.47%3.14M shares |
Woodline Partners LP | 2.37%3.01M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.93%2.45M shares |
Siren, L.L.C. | 1.91%2.42M shares |
ROSEN TERRY J | ≈1.76%2.24M shares |
Fisher Asset Management, LLC | 1.68%2.14M shares |
MARSHALL WACE, LLP | 1.53%1.95M shares |
SAMLYN CAPITAL, LLC | 1.22%1.55M shares |
DIMENSIONAL FUND ADVISORS LP | 1.13%1.43M shares |
BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.12%1.42M shares |
GOLDMAN SACHS GROUP INC | 1.09%1.39M shares |
Jaen Juan C. | ≈1.00%1.27M shares |
Percentages use 127M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 · 10b5-1 | Jaen Juan C.President | SellCommon Stock · indirect | 6.4K | $29.66 | $190.7K | 890.8K |
| Jun 23, 2026Form 4 · 10b5-1 | Jaen Juan C.President | SellCommon Stock · indirect | 1.7K | $28.06 | $47.6K | 897.2K |
| Jun 23, 2026Form 4 · 10b5-1 | Jaen Juan C.President | SellCommon Stock · indirect | 14.1K | $27.69 | $389.5K | 898.9K |
| Jun 22, 2026Form 4 · 10b5-1 | Jaen Juan C.President | SellCommon Stock · indirect | 9.2K | $27.03 | $249.6K | 913.0K |
| Jun 1, 2026Form 4 · 10b5-1 | Azoy AlexanderChief Accounting Officer | SellCommon Stock | 2.6K | $25.77 | $66.0K | 39.6K |